Why script-to-dispense conversion will take centre stage in 2023
pharmaphorum
JANUARY 6, 2023
In 2023, expect manufacturers to further shift their focus away from acquiring new patient prescriptions to retaining existing customers. The account carried an official blue check mark, but in fact it did not belong to the prescription drugmaker. in 1979 to 2.8%in Ensuring patient access.
Let's personalize your content